NGeneBio Appoints New Chief Data Officer to Accelerate Genomic Data Business Expansion

Dr. Jenny Song, Expert in Gene Therapy and Drug Development Who Participated in the Development of Luxturna, Joins NGeneBio

Strengthening Data Business Strategy Based on Experience in Gene Therapy and Drug Development

Plans to Build Collaboration Models with Pharmaceutical and Biotechnology Companies Utilizing Genomic Data

NGeneBio, an AI precision medicine company, announced on June 15 that it has appointed Dr. Jenny Song as Chief Data Officer (CDO) to expand its genomic data business.

Jenny Song, the new Chief Data Officer (CDO) at NGENBio. NGENBio

With the establishment of the new CDO position, NGeneBio plans to leverage its accumulated genomic data, based on its network of medical institutions, to expand its data business targeting pharmaceutical and biotechnology companies.

CDO Song holds a Ph.D. in Life Sciences from KAIST and is an expert with research and business development experience in gene therapy and new drug development. She has been involved in the entire process of developing adeno-associated virus (AAV) gene therapies and mRNA therapeutics, and participated in the development of the hereditary blindness treatment 'Luxturna'.

Afterward, she was responsible for establishing mRNA and gene therapy development strategies and technology commercialization at the Mogam Institute for Biomedical Research and GC Biopharma, accumulating business development experience through open innovation and licensing.

NGeneBio plans to build data business models that go beyond the collection and analysis of genomic data, enabling their use in research and new drug development processes, with CDO Song at the center. The company also aims to strengthen its data-driven precision medicine business by expanding collaborations with domestic and global pharmaceutical and biotechnology companies.

CDO Jenny Song stated, "I will establish data business models that researchers and pharmaceutical companies can actually use in the research and development process, and enhance the value of utilizing genomic data."

This content was produced with the assistance of AI translation services.